Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.

被引:13
作者
Koshkin, Vadim S.
Sonpavde, Guru P.
Hwang, Clara
Mellado, Begona
Tomlinson, Gareth
Shimura, Masashi
Chisamore, Michael Jon
Gil, Maciej
Loriot, Yohann
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[3] Henry Ford Hlth Syst, Detroit, MI USA
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Taiho Pharma Canada Inc, Oakville, ON, Canada
[6] Taiho Oncol Inc, Princeton, NJ USA
[7] Merck & Co Inc, Kenilworth, NJ USA
[8] Univ Paris Saclay, Gustave Roussy, INSERMU981, Villejuif, France
关键词
D O I
10.1200/JCO.2022.40.6_suppl.501
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
501
引用
收藏
页数:3
相关论文
empty
未找到相关数据